Hilary Eaton, Ph.D.

Hilary Eaton is the VP and Head of Transactions and M&A for Genetic Medicine and AI at Eli Lilly. She is a rare disease patient-advocate passionate about developing next-generation genetic medicines to cure monogenic disorders, with more than a decade driving business development and partnerships at leading gene editing companies, including Editas, Vor, Tome, and Profluent. Prior to her career in business development, Hilary received her PhD from Duke University and completed a postdoc at Harvard Medical School and Dana-Farber Cancer Institute. Her daughter was recently diagnosed with Okur-Chung Neurodevelopmental Syndrome, and Hilary hopes to mesh professional and personal interests in support of the groundbreaking work ongoing at the CSNK2A1 Foundation.